传染病信息

参考文献

[1]Torre LA,Bray F,Siegel RL,Ferlay J,Lortet-Tieulent J,Jemal A.Global cancer statistics,2012.CA Cancer J Clin 2015;65:87-108.

[2]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015.CA Cancer J Clin 2016;66:115-32.

[3]Zhang BH,Yang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol 2004;130:417-22.

[4]Zeng MS,Ye HY,Guo L,et al.Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients:a multicenter,open-label,phase III study.Hepatobiliary Pancreat Dis Int 2013;12:607-16.

[5]Lee YJ,Lee JM,Lee JS,et al.Hepatocellular carcinoma:diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis.Radiology 2015;275:97-109.

[6]Ichikawa T,Saito K,Yoshioka N,et al.Detection and characterization of focal liver lesions:a Japanese phase III,multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.Invest Radiol 2010;45:133-41.

[7]丁莺,陈财忠,饶圣祥,曾蒙苏.Gd+-EOB-DTPA与Gd+-DTPA增强磁共振检查肝细胞癌的对照研究.中华普通外科杂志2013;28:682-5.

[8]Yoo SH,Choi JY,Jang JW,et al.Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma.Ann Surg Oncol 2013;20:2893-900.

[9]Chen CZ,Rao SX,Ding Y,et al.Hepatocellular carcinoma 20 mm or smaller in cirrhosis patients:early magnetic resonance enhancement by gadoxetic acid compared with gadopentetate dimeglumine.Hepatol Int 2014;8:104-11.

[10]Chen BB,Murakami T,Shih TT,et al.Novel imaging diagnosis for hepatocellular carcinoma:consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting(APPLE 2014).Liver Cancer 2015;4:215-27.

[11]Merkle EM,Zech CJ,Bartolozzi C,et al.Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging.Eur Radiol 2016;26:674-82.

[12]Park JW,Kim JH,Kim SK,et al.A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.J Nucl Med 2008;49:1912-21.

[13]Lin CY,Chen JH,Liang JA,Lin CC,Jeng LB,Kao CH.18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma:a systematic review and meta-analysis.Eur J Radiol 2012;81:2417-22.

[14]Boellaard R,Delgado-Bolton R,Oyen WJ,et al.FDG PET/CT:EANM procedure guidelines for tumour imaging:version 2.0.Eur J Nucl Med Mol Imaging 2015;42:328-54.

[15]Boellaard R,O'Doherty MJ,Weber WA,et al.FDG PET and PET/CT:EANM procedure guidelines for tumour PET imaging:version 1.0.Eur J Nucl Med Mol Imaging 2010;37:181-200.

[16]Wahl RL,Jacene H,Kasamon Y,Lodge MA.From RECIST to PERCIST:Evolving Considerations for PET response criteria in solid tumors.J Nucl Med 2009;50 Suppl 1:122S-50S.

[17]Chalian H,Tore HG,Horowitz JM,Salem R,Miller FH,Yaghmai V.Radiologic assessment of response to therapy:comparison of RECIST Versions 1.1 and 1.0.Radiographics 2011;31:2093-105.

[18]Ferda J,Ferdova E,Baxa J,et al.The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing,grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography.Anticancer Res 2015;35:2241-6.

[19]Lee JW,Oh JK,Chung YA,et al.Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy:A Multicenter Retrospective Cohort Study.J Nucl Med 2016;57:509-16.

[20]Hyun SH,Eo JS,Lee JW,et al.Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas:a multicenter retrospective cohort study.Eur J Nucl Med Mol Imaging 2016.

[21]Bertagna F,Bertoli M,Bosio G,et al.Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma:a systematic review and meta-analysis.Hepatol Int 2014;8:493-500.

[22]Cheung TT,Ho CL,Lo CM,et al.11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria:surgeon's perspective.J Nucl Med 2013;54:192-200.

[23]Zhang Y,Shi H,Li B,Cai L,Gu Y,Xiu Y.The added value of SPECT/spiral CT in patients with equivocal bony metastasis from hepatocellular carcinoma.Nuklearmedizin 2015;54:255-61.

[24]Forner A,Vilana R,Ayuso C,et al.Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis:Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.Hepatology 2008;47:97-104.

[25]陈孝平.肝恶性肿瘤.In:陈孝平,ed.外科学.第2版ed.北京:人民卫生出版社;2010:620.

[26]Westra WH,Hruban RH,Phelps TH,Isacson C.Surgical Pathology Dissection:An Illustrated Guide.New York:Springer;2003.

[27]Nara S,Shimada K,Sakamoto Y,et al.Prognostic impact of marginal resection for patients with solitary hepatocellular carcinoma:evidence from 570 hepatectomies.Surgery 2012;151:526-36.

[28]丛文铭.肝细胞性恶性肿瘤.In:丛文铭,ed.肝胆肿瘤外科病理学.1 ed.北京:人民卫生出版社;2015:276-320.

[29]Scheuer PJ.Classification of chronic viral hepatitis:a need for reassessment.J Hepatol 1991;13:372-4.

[30]病毒性肝炎防治方案.中华传染病杂志2001;19:56-62.

[31]Guidelines for the Prevention,Care and Treatment of Persons with Chronic Hepatitis B Infection.Geneva2015.

[32]Rodriguez-Peralvarez M,Luong TV,Andreana L,Meyer T,Dhillon AP,Burroughs AK.A systematic review of microvascular invasion in hepatocellular carcinoma:diagnostic and prognostic variability.Ann Surg Oncol 2013;20:325-39.

[33]中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,et al.原发性肝癌规范化病理诊断指南(2015年版).中华肝胆外科杂志2015;21:145-51.

[34]Eguchi S,Takatsuki M,Hidaka M,et al.Predictor for histological microvascular invasion of hepatocellular carcinoma:a lesson from 229 consecutive cases of curative liver resection.World J Surg 2010;34:1034-8.

[35]Fujita N,Aishima S,Iguchi T,et al.Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma.Hum Pathol 2011;42:1531-8.

[36]Iguchi T,Shirabe K,Aishima S,et al.New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma:Predicting Prognosis After Living-donor Liver Transplantation.Transplantation 2015;99:1236-42.

[37]Imamura H,Seyama Y,Kokudo N,et al.One thousand fifty-six hepatectomies without mortality in 8 years.Arch Surg 2003;138:1198-206;discussion 206.

[38]Kubota K,Makuuchi M,Kusaka K,et al.Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors.Hepatology 1997;26:1176-81.

[39]Bruix J,Castells A,Bosch J,et al.Surgical resection of hepatocellular carcinoma in cirrhotic patients:prognostic value of preoperative portal pressure.Gastroenterology 1996;111:1018-22.

[40]Cescon M,Colecchia A,Cucchetti A,et al.Value of transient elastography measured with Fibro Scan in predicting the outcome of hepatic resection for hepatocellular carcinoma.Ann Surg 2012;256:706-12;discussion 12-3.

[41]Chen MS,Li JQ,Zheng Y,et al.A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma.Ann Surg 2006;243:321-8.

[42]Liu PH,Hsu CY,Hsia CY,et al.Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma

[43]Feng K,Yan J,Li X,et al.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma.J Hepatol 2012;57:794-802.

[44]Xu Q,Kobayashi S,Ye X,Meng X.Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma:a meta-analysis of 16,103 patients.Sci Rep 2014;4:7252.

[45]Yin L,Li H,Li AJ,et al.Partial hepatectomy vs.transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria:a RCT.J Hepatol 2014;61:82-8.

[46]Torzilli G,Belghiti J,Kokudo N,et al.A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers:is it adherent to the EASL/AASLD recommendations?:an observational study of the HCC East-West study group.Ann Surg 2013;257:929-37.

[47]Ishizawa T,Hasegawa K,Aoki T,et al.Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.Gastroenterology 2008;134:1908-16.

[48]Jiang HT,Cao JY.Impact of laparoscopic versus open hepatectomy on perioperative clinical outcomes of patients with primary hepatic carcinoma.Chin Med Sci J 2015;30:80-3.

[49]Tang ZY,Uy YQ,Zhou XD,et al.Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma:evaluation with analysis of 72 patients.World J Surg 1995;19:784-9.

[50]Tang ZY,Yu YQ,Zhou XD,et al.Treatment of unresectable primary liver cancer:with reference to cytoreduction and sequential resection.World J Surg 1995;19:47-52.

[51]Wakabayashi H,Okada S,Maeba T,Maeta H.Effect of preoperative portal vein embolization on major hepatectomy for advanced-stage hepatocellular carcinomas in injured livers:a preliminary report.Surg Today 1997;27:403-10.

[52]Ogata S,Belghiti J,Farges O,Varma D,Sibert A,Vilgrain V.Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma.Br J Surg 2006;93:1091-8.

[53]周俭,王征,孙健,等.联合肝脏离断和门静脉结扎的二步肝切除术.中华消化外科杂志,2013;12:485-489

[54]D'Haese JG,Neumann J,Weniger M,et al.Should ALPPS be Used for Liver Resection in Intermediate-Stage HCC?Ann Surg Oncol 2016;23:1335-43..

[55]Hong de F,Zhang YB,Peng SY,Huang DS.Percutaneous Microwave Ablation Liver Partition and Portal Vein Embolization for Rapid Liver Regeneration:A Minimally Invasive First Step of ALPPS for Hepatocellular Carcinoma.Ann Surg 2016;264:e1-2.

[56]Liu CL,Fan ST,Lo CM,Tung-Ping Poon R,Wong J.Anterior approach for major right hepatic resection for large hepatocellular carcinoma.Ann Surg 2000;232:25-31.

[57]Zhang ZM,Lai EC,Zhang C,et al.The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus.Int J Surg 2015;20:8-16.

[58]Fu SY,Lau WY,Li AJ,et al.Liver resection under total vascular exclusion with or without preceding Pringle manoeuvre.Br J Surg 2010;97:50-5.

[59]Satoh S,Ikai I,Honda G,et al.Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi.Surgery 2000;128:779-83.

[60]Shi HY,Wang SN,Wang SC,Chuang SC,Chen CM,Lee KT.Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma:a nationwide Taiwan database analysis of long-term outcome predictors.J Surg Oncol 2014;109:487-93.

[61]Zhou WP,Lai EC,Li AJ,et al.A prospective,randomized,controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma.Ann Surg 2009;249:195-202.

[62]Ren ZG,Lin ZY,Xia JL,et al.Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor:a retrospective control study.World J Gastroenterol 2004;10:2791-4.

[63]Fan J,Zhou J,Wu ZQ,et al.Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis.World J Gastroenterol 2005;11:1215-9.

[64]Lo CM,Liu CL,Chan SC,et al.A randomized,controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.Ann Surg 2007;245:831-42.

[65]Sun HC,Tang ZY,Wang L,et al.Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma:a randomized clinical trial.J Cancer Res Clin Oncol 2006;132:458-65.

[66]Nishiguchi S,Tamori A,Kubo S.Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma.Intervirology 2005;48:71-5.

[67]Mazzaferro V,Romito R,Schiavo M,et al.Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.Hepatology 2006;44:1543-54.

[68]Ji J,Shi J,Budhu A,et al.Micro RNA expression,survival,and response to interferon in liver cancer.N Engl J Med 2009;361:1437-47.

[69]Yin J,Li N,Han Y,et al.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma:a two-stage longitudinal clinical study.J Clin Oncol 2013;31:3647-55.

[70]Huang G,Lau WY,Wang ZG,et al.Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma:a randomized controlled trial.Ann Surg 2015;261:56-66.

[71]Zheng SS,Xu X,Wu J,et al.Liver transplantation for hepatocellular carcinoma:Hangzhou experiences.Transplantation 2008;85:1726-32.

[72]Fan J,Yang GS,Fu ZR,et al.Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients:a multi-center experience in Shanghai,China.J Cancer Res Clin Oncol 2009;135:1403-12.

[73]Li J,Yan LN,Yang J,et al.Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients.World J Gastroenterol 2009;15:4170-6.

[74]邵卓,杨广顺,杨宁,et al.三亚共识在原发性肝癌肝移植治疗中的运用.中国实用外科杂志2008;28:466-9.

[75]Rodriguez-Peralvarez M,Tsochatzis E,Naveas MC,et al.Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.J Hepatol 2013;59:1193-9.

[76]Liang W,Wang D,Ling X,et al.Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma:a meta-analysis.Liver Transpl 2012;18:62-9.

[77]Zhou J,Wang Z,Wu ZQ,et al.Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.Transplant Proc 2008;40:3548-53.

[78]Hasegawa K,Aoki T,Ishizawa T,et al.Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinoma.Ann Surg Oncol 2014;21 Suppl 3:S348-55.

[79]Li L,Zhang J,Liu X,Li X,Jiao B,Kang T.Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma:a meta-analysis.J Gastroenterol Hepatol 2012;27:51-8.

[80]Huang J,Yan L,Cheng Z,et al.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.Ann Surg 2010;252:903-12.

[81]Peng ZW,Zhang YJ,Chen MS,et al.Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma:a prospective randomized trial.J Clin Oncol 2013;31:426-32.

[82]Morimoto M,Numata K,Kondou M,Nozaki A,Morita S,Tanaka K.Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma:a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization.Cancer 2010;116:5452-60.

[83]Di Vece F,Tombesi P,Ermili F,Maraldi C,Sartori S.Coagulation areas produced by cool-tip radiofrequency ablation and microwave ablation using a device to decrease back-heating effects:a prospective pilot study.Cardiovasc Intervent Radiol 2014;37:723-9.

[84]Lencioni R,de Baere T,Soulen MC,Rilling WS,Geschwind JF.Lipiodol transarterial chemoembolization for hepatocellular carcinoma:A systematic review of efficacy and safety data.Hepatology 2016;64:106-16.

[85]Pelletier G,Ducreux M,Gay F,et al.Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization:a multicenter randomized trial.Groupe CHC.J Hepatol 1998;29:129-34.

[86]Lo CM,Ngan H,Tso WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.Hepatology 2002;35:1164-71.

[87]Llovet JM,Real MI,Montana X,et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial.Lancet 2002;359:1734-9.

[88]Camma C,Schepis F,Orlando A,et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma:meta-analysis of randomized controlled trials.Radiology 2002;224:47-54.

[89]Llovet JM,Bruix J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:Chemoembolization improves survival.Hepatology 2003;37:429-42.

[90]中华医学会放射学分会介入学组协作组.原发性肝细胞癌经导管肝动脉化疗性栓塞治疗技术操作规范专家共识.中华放射学杂志2011;45:908-12.

[91]Yang M,Fang Z,Yan Z,et al.Transarterial chemoembolisation(TACE)combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone:a two-arm,randomised clinical trial.J Cancer Res Clin Oncol 2014;140:211-9.

[92]Si ZM,Wang GZ,Qian S,et al.Combination Therapies in the Management of Large(>/=5 cm)Hepatocellular Carcinoma:Microwave Ablation Immediately Followed by Transarterial Chemoembolization.J Vasc Interv Radiol 2016.

[93]Zeng ZC,Tang ZY,Fan J,et al.A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma.Cancer J 2004;10:307-16.

[94]Meng MB,Cui YL,Lu Y,et al.Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma:a systematic review and meta-analysis.Radiother Oncol 2009;92:184-94.

[95]Zeng ZC,Fan J,Tang ZY,et al.A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus.Int J Radiat Oncol Biol Phys 2005;61:432-43.

[96]Zeng ZC,Tang ZY,Fan J,et al.Consideration of role of radiotherapy for lymph node metastases in patients with HCC:retrospective analysis for prognostic factors from 125 patients.Int J Radiat Oncol Biol Phys 2005;63:1067-76.

[97]Zhou LY,Zeng ZC,Fan J,et al.Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma:clinical features and prognostic factors.Bmc Cancer 2014;14:878-87.

[98]He J,Zeng ZC,Tang ZY,et al.Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy.Cancer 2009;115:2710-20.

[99]Wang WH,Wang Z,Wu JX,et al.Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels.Liver Int 2015;35:2603-10.

[100]Wang MH,Ji Y,Zeng ZC,et al.Impact factors for microinvasion in patients with hepatocellular carcinoma:possible application to the definition of clinical tumor volume.Int J Radiat Oncol Biol Phys 2010;76:467-76.

[101]曾昭冲.肝细胞癌的立体定向放射治疗.中华肿瘤杂志2015:650-2,3.

[102]Dawson LA,Normolle D,Balter JM,Mc Ginn CJ,Lawrence TS,Ten Haken RK.Analysis of radiation-induced liver disease using the Lyman NTCP model.Int J Radiat Oncol Biol Phys 2002;53:810-21.

[103]Liang SX,Zhu XD,Xu ZY,et al.Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma:the risk factors and hepatic radiation tolerance.Int J Radiat Oncol Biol Phys 2006;65:426-34.

[104]Chon YE,Seong J,Kim BK,et al.Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma:endoscopic findings and risk factors.Int J Radiat Oncol Biol Phys 2011;81:1343-51.

[105]Hou JZ,Zeng ZC,Wang BL,Yang P,Zhang JY,Mo HF.High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT.Jpn J Clin Oncol 2016;46:357-62.

[106]Hu Y,Zhou YK,Chen YX,Shi SM,Zeng ZC.4D-CT scans reveal reduced magnitude of respiratory liver motion achieved by different abdominal compression plate positions in patients with intrahepatic tumors undergoing helical tomotherapy.Med Phys 2016;43:4335.

[107]Lau WY,Teoh YL,Win KM,et al.Current role of selective internal radiation with yttrium-90 in liver tumors.Future Oncol 2016;12:1193-204.

[108]Xu J,Shen ZY,Chen XG,et al.A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation.Hepatology 2007;45:269-76.

[109]Raoul JL,Guyader D,Bretagne JF,et al.Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis:intra-arterial iodine-131-iodized oil versus medical support.J Nucl Med 1994;35:1782-7.

[110]Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med 2008;359:378-90.

[111]Pressiani T,Boni C,Rimassa L,et al.Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma:a prospective feasibility analysis.Ann Oncol 2013;24:406-11.

[112]Qin S,Bai Y,Lim HY,et al.Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.J Clin Oncol 2013;31:3501-8.

[113]Lee JH,Lee JH,Lim YS,et al.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.Gastroenterology 2015;148:1383-91 e6.

[114]程树群,吴孟超,陈汉,et al.胸腺肽α1对原发性肝癌术后复发的影响.中华肝胆外科杂志2004;10:592-3.

[115]Xu L,Wang J,Kim Y,et al.A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma.Oncoimmunology 2016;5:e1083671.

[116]高继良.肝复乐方剂治疗晚期原发性肝癌的前瞻性、随机对照临床研究.中国中药杂志2014;39:2367-9.

[117]阎涛,毕新宇,方仪,et al.槐耳颗粒对原发性肝癌病人病人术后长期生存的影响.中华肝胆外科杂志2012;18:99-102.

[118]Zeeneldin AA,Eid SM,Darweesh AD,Moneer MM,Saadeldin M.Tamoxifen compared to best supportive care in advanced hepatocelluar carcinoma:a retrospective matched-cohort study.J Egypt Natl Canc Inst 2014;26:1-7.

[119]Sato Y,Watanabe H,Sone M,et al.Tumor response evaluation criteria for HCC(hepatocellular carcinoma)treated using TACE(transcatheter arterial chemoembolization):RECIST(response evaluation criteria in solid tumors)version 1.1 and m RECIST(modified RECIST):JIVROSG-0602.Ups J Med Sci 2013;118:16-22.

[120]Wolchok JD,Hoos A,O'Day S,et al.Guidelines for the evaluation of immune therapy activity in solid tumors:immune-related response criteria.Clin Cancer Res 2009;15:7412-20.

[121]任秀宝,于津浦.肿瘤免疫治疗疗效评价的新标准.中国肿瘤生物治疗杂志2011;18:351-4.